Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07283822 · ClinicalTrials.gov registry record · Phase 2
Amping up With PemJAK
A Phase 2 study of Non-Hodgkin Lymphoma and Peripheral T-Cell Lymphoma, sponsored by Seda S. Tolu.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT07283822: Recruiting Phase 2 study of Non-Hodgkin Lymphoma and Peripheral T-Cell Lymphoma, sponsored by Seda S. Tolu.
NCT07283822 is a Phase 2 study of Non-Hodgkin Lymphoma and Peripheral T-Cell Lymphoma that is actively recruiting participants, run by Seda S. Tolu. The registered enrollment target is 53 participants, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07283822, a Phase 2 study of Non-Hodgkin Lymphoma and Peripheral T-Cell Lymphoma, is actively recruiting participants, sponsored by Seda S. Tolu.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
Primary Outcome
For Arm 1, in patients with Peripheral T-cell Lymphoma (PTCL), the primary objective will be complete response (CR) rate.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Ruxolitinib
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2029-01 |
| Phase | Phase 2 |
What NCT07283822 shows while recruiting
NCT07283822 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 167-participant average among 106 other Non-Hodgkin Lymphoma trials with a reported enrollment target (68% lower).
The record links to 8 conditions, with Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07283822 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07283822 about?
NCT07283822 is a clinical study titled "Amping up With PemJAK". The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.
What is the current status of trial NCT07283822?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2025-12-03. Estimated completion is 2029-01.
What conditions does trial NCT07283822 study?
This clinical trial studies the following conditions: Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Hodgkin Disease Recurrent.
What interventions are being tested in trial NCT07283822?
The interventions under investigation include: Pembrolizumab (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT07283822?
This trial is sponsored by Seda S. Tolu, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07283822 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07283822's enrollment target sits among peer trials
53 55th of 106 higher than 52 of 106 other Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
RECRUITING · Phase 2
-
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
-
Epco, Zanu, Ritux for R/R FL or MZL
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI